$30.91
0.45% yesterday
Nasdaq, Sep 20, 10:02 pm CET
ISIN
US24823R1059
Symbol
DNLI
Sector
Industry

Denali Therapeutics Inc. Stock price

$30.91
+7.26 30.70% 1M
+9.62 45.19% 6M
+9.45 44.04% YTD
+8.69 39.11% 1Y
-18.95 38.01% 3Y
+12.81 70.77% 5Y
+9.46 44.10% 10Y
Nasdaq, Closing price Fri, Sep 20 2024
-0.14 0.45%
ISIN
US24823R1059
Symbol
DNLI
Sector
Industry

Key metrics

Market capitalization $4.43b
Enterprise Value $3.58b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2,817.28
P/S ratio (TTM) P/S ratio 3,484.43
P/B ratio (TTM) P/B ratio 3.19
Revenue growth (TTM) Revenue growth -99.63%
Revenue (TTM) Revenue $1.27m
EBIT (operating result TTM) EBIT $-495.21m
Free Cash Flow (TTM) Free Cash Flow $-402.10m
Cash position $896.04m
EPS (TTM) EPS $-2.85
P/E forward negative
P/S forward 246.83
EV/Sales forward 199.57
Short interest 7.37%
Show more

Is Denali Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Denali Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Denali Therapeutics Inc. forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Denali Therapeutics Inc. forecast:

Buy
93%
Hold
7%

Financial data from Denali Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
1.27 1.27
100% 100%
100%
- Direct Costs 8.50 8.50
43% 43%
669%
-7.23 -7.23
102% 102%
-569%
- Selling and Administrative Expenses 84 84
19% 19%
6,577%
- Research and Development Expense 396 396
3% 3%
31,178%
-487 -487
229% 229%
-38,324%
- Depreciation and Amortization 8.50 8.50
43% 43%
669%
EBIT (Operating Income) EBIT -495 -495
204% 204%
-38,993%
Net Profit -420 -420
227% 227%
-33,043%

In millions USD.

Don't miss a Thing! We will send you all news about Denali Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Denali Therapeutics Inc. Stock News

Neutral
GlobeNewsWire
18 days ago
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the outcome of a recent successful meeting with the Center for Drug Evaluation and Research (CDER) division of the U.S. Food and Drug Administration (FDA) providing a path to filing a biologics license application (BLA) for accelerated approval and subsequent conversion to ful...
Positive
Seeking Alpha
about one month ago
Denali Therapeutics' proprietary Transport Vehicle technology enables drug delivery across the blood-brain barrier, targeting neurodegenerative diseases. DNL310, targeting MPS II, and DNL343 for ALS are key drug candidates with potential, though competition is significant. The company's $500 million capital raise supports its aggressive R&D investment, providing a runway for developing its pipe...
Neutral
GlobeNewsWire
about one month ago
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage diseases, today announced publication of nonclinical data in the August 14, 2024 issue of Science Trans...
More Denali Therapeutics Inc. News

Company Profile

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Head office United States
CEO Ryan Watts
Employees 445
Founded 2013
Website www.denalitherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today